Search
Article

Monitoring Roche NT-proBNP in heart failure patients can provide powerful prognostic information

Gain insights regarding disease progression by using Roche NT-proBNP to monitor heart failure patients.

 

The trend in NT-proBNP levels in heart failure (HF) patients over time gives valuable prognostic information.1,2 The use of Roche NT-proBNP test to monitor patients helps to: 

  • Identify patients that appear to be doing well symptomatically, yet whose underlying disease is still not in contol3
  • Avoid prescribing inertia and ensure your patients' treatment is effective4

 

Make the right choice in biomarker at every stage of care with Roche NT-proBNP. 

 

In the era of angiotensin receptor-neprilysin inhibitor (ARNi) therapy, the choice in biomarker for HF patients becomes increasingly important. Active B-type natriuretic peptide (BNP) is a neprilysin substrate, making BNP an unsuitable biomarker in HF patients treated with sacubitril-valsartan.4-9 The use of Roche NT-proBNP can help support your clinical decisions to provide the best patient care - especially when a patient's medication regimen is unknown at the time of presenting. 

 

Trend in Roche NT-proBNP concentration over time can give important prognostic information.1,2

Roche NT-proBNP prognosticator chart
  • Elevated Roche NT-proBNP values are strongly predictive of adverse outcomes and rising values identify a rising risk8,10,11
  • Significant lowering of Roche NT-proBNP is associated with better prognosis and improved clinical outcomes8,10-13
  • In PARADIGM-HF, changes in Roche NT-proBNP over the course of HF provided important prognostic information and can help to identify patients at risk of hospitalization for HF and mortality1,2,8
Do you have any questions?
Contact Us

Abbreviations

NT-proBNP: N-terminal prohormone of brain natriuretic peptide

 

References 

  1. Masson et al. (2008). J Am Coll Cardiol. 52, 997-100
  2. Januzzi (2012). Arch Cardiovasc Dis. 105, 40-50
  3. Pellicori et al. (2017). Eur J Heart Failure. 19, 768-778 
  4. Yancy et al. (2017). Circulation. 136, e137 – e161
  5. Entresto. Summary of Product Characteristics. EMA approval. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004062/WC500197536.pdf [Accessed on January 23th, 2018]
  6. Januzzi (2016). Clin Chem. 62(5), 663-665
  7. Entresto, Switzerland approval. Fachinformation des Arzneimittel-Kompendium der Schweiz®, Compendium.ch: https://compendium.ch/mpro/mnr/26799/html/de [Accessed on January 24th, 2018]
  8. Zile et al (2016). J Am Coll Cardiol. 68, 2425-2436
  9. McKie and Burnett (2016). J Am Coll Cardiol. 62, 2437-2439
  10. Chiong et al. (2010). Heart Fail Rev. 15, 275-291
  11. Weiner et al. (2012). Eur J Heart Fail. 15, 342-351
  12. Gaggin et al. (2013). Congest Heart Fail. 19, 135-42
  13. Deberadinis and Januzzi. (2012). Curr Opin Cardiol. 27, 661-668